Cargando…

Evaluation of two treatment strategies for the prevention of preterm birth in women identified as at risk by ultrasound (PESAPRO Trial): study protocol for a randomized controlled trial

BACKGROUND: Premature birth is considered one of the main problems in modern Obstetrics. It causes more than 50 % of neonatal mortality; it is responsible for a large proportion of infant morbidity and incurs very high economic costs. Cervical length, which can be accurately measured by ultrasound,...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabrera-García, Lourdes, Cruz-Melguizo, Sara, Ruiz-Antorán, Belén, Torres, Ferrán, Velasco, Ana, Martínez-Payo, Cristina, Avendaño-Solá, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584019/
https://www.ncbi.nlm.nih.gov/pubmed/26407852
http://dx.doi.org/10.1186/s13063-015-0964-y
_version_ 1782391923553599488
author Cabrera-García, Lourdes
Cruz-Melguizo, Sara
Ruiz-Antorán, Belén
Torres, Ferrán
Velasco, Ana
Martínez-Payo, Cristina
Avendaño-Solá, Cristina
author_facet Cabrera-García, Lourdes
Cruz-Melguizo, Sara
Ruiz-Antorán, Belén
Torres, Ferrán
Velasco, Ana
Martínez-Payo, Cristina
Avendaño-Solá, Cristina
author_sort Cabrera-García, Lourdes
collection PubMed
description BACKGROUND: Premature birth is considered one of the main problems in modern Obstetrics. It causes more than 50 % of neonatal mortality; it is responsible for a large proportion of infant morbidity and incurs very high economic costs. Cervical length, which can be accurately measured by ultrasound, has an inverse relationship with the risk of preterm birth. As a result, having an effective intervention for asymptomatic patients with short cervix could reduce the prematurity. Although recently published data demonstrates the effectiveness of vaginal progesterone and cervical pessary, these treatments have never been compared to one another. METHODS/DESIGN: The PESAPRO study is a noncommercial, multicenter, open-label, randomized clinical trial (RCT) in pregnant women with a short cervix as identified by transvaginal ultrasonography at 19 to 22 weeks of gestation. Patients are randomized (1:1) to either daily vaginal progesterone or cervical pessary until the 37th week of gestation or delivery; whichever comes first. During the trial, women visit every 4 weeks for routine questions and tests. The primary outcome is the proportion of spontaneous preterm deliveries before 34 weeks of gestation. A sample size of 254 pregnant women will be included at 29 participating hospitals in order to demonstrate noninferiority of placing a pessary versus vaginal progesterone. The first patient was randomized in August 2012, and recruitment of study subjects will continue until the end of December 2015. DISCUSSION: This trial assesses the comparative efficacy and safety between two accepted treatments, cervical pessary versus vaginal progesterone, and it will provide evidence in order to establish clinical recommendations. TRIAL REGISTRATION: EU Clinical Trials Register EudraCT2012-000241-13 (Date of registration: 16 January 2012); ClinicalTrials.gov Identifier NCT01643980 (Date of registration: 12 June 2012).
format Online
Article
Text
id pubmed-4584019
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45840192015-09-28 Evaluation of two treatment strategies for the prevention of preterm birth in women identified as at risk by ultrasound (PESAPRO Trial): study protocol for a randomized controlled trial Cabrera-García, Lourdes Cruz-Melguizo, Sara Ruiz-Antorán, Belén Torres, Ferrán Velasco, Ana Martínez-Payo, Cristina Avendaño-Solá, Cristina Trials Study Protocol BACKGROUND: Premature birth is considered one of the main problems in modern Obstetrics. It causes more than 50 % of neonatal mortality; it is responsible for a large proportion of infant morbidity and incurs very high economic costs. Cervical length, which can be accurately measured by ultrasound, has an inverse relationship with the risk of preterm birth. As a result, having an effective intervention for asymptomatic patients with short cervix could reduce the prematurity. Although recently published data demonstrates the effectiveness of vaginal progesterone and cervical pessary, these treatments have never been compared to one another. METHODS/DESIGN: The PESAPRO study is a noncommercial, multicenter, open-label, randomized clinical trial (RCT) in pregnant women with a short cervix as identified by transvaginal ultrasonography at 19 to 22 weeks of gestation. Patients are randomized (1:1) to either daily vaginal progesterone or cervical pessary until the 37th week of gestation or delivery; whichever comes first. During the trial, women visit every 4 weeks for routine questions and tests. The primary outcome is the proportion of spontaneous preterm deliveries before 34 weeks of gestation. A sample size of 254 pregnant women will be included at 29 participating hospitals in order to demonstrate noninferiority of placing a pessary versus vaginal progesterone. The first patient was randomized in August 2012, and recruitment of study subjects will continue until the end of December 2015. DISCUSSION: This trial assesses the comparative efficacy and safety between two accepted treatments, cervical pessary versus vaginal progesterone, and it will provide evidence in order to establish clinical recommendations. TRIAL REGISTRATION: EU Clinical Trials Register EudraCT2012-000241-13 (Date of registration: 16 January 2012); ClinicalTrials.gov Identifier NCT01643980 (Date of registration: 12 June 2012). BioMed Central 2015-09-25 /pmc/articles/PMC4584019/ /pubmed/26407852 http://dx.doi.org/10.1186/s13063-015-0964-y Text en © Cabrera-García et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Cabrera-García, Lourdes
Cruz-Melguizo, Sara
Ruiz-Antorán, Belén
Torres, Ferrán
Velasco, Ana
Martínez-Payo, Cristina
Avendaño-Solá, Cristina
Evaluation of two treatment strategies for the prevention of preterm birth in women identified as at risk by ultrasound (PESAPRO Trial): study protocol for a randomized controlled trial
title Evaluation of two treatment strategies for the prevention of preterm birth in women identified as at risk by ultrasound (PESAPRO Trial): study protocol for a randomized controlled trial
title_full Evaluation of two treatment strategies for the prevention of preterm birth in women identified as at risk by ultrasound (PESAPRO Trial): study protocol for a randomized controlled trial
title_fullStr Evaluation of two treatment strategies for the prevention of preterm birth in women identified as at risk by ultrasound (PESAPRO Trial): study protocol for a randomized controlled trial
title_full_unstemmed Evaluation of two treatment strategies for the prevention of preterm birth in women identified as at risk by ultrasound (PESAPRO Trial): study protocol for a randomized controlled trial
title_short Evaluation of two treatment strategies for the prevention of preterm birth in women identified as at risk by ultrasound (PESAPRO Trial): study protocol for a randomized controlled trial
title_sort evaluation of two treatment strategies for the prevention of preterm birth in women identified as at risk by ultrasound (pesapro trial): study protocol for a randomized controlled trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584019/
https://www.ncbi.nlm.nih.gov/pubmed/26407852
http://dx.doi.org/10.1186/s13063-015-0964-y
work_keys_str_mv AT cabreragarcialourdes evaluationoftwotreatmentstrategiesforthepreventionofpretermbirthinwomenidentifiedasatriskbyultrasoundpesaprotrialstudyprotocolforarandomizedcontrolledtrial
AT cruzmelguizosara evaluationoftwotreatmentstrategiesforthepreventionofpretermbirthinwomenidentifiedasatriskbyultrasoundpesaprotrialstudyprotocolforarandomizedcontrolledtrial
AT ruizantoranbelen evaluationoftwotreatmentstrategiesforthepreventionofpretermbirthinwomenidentifiedasatriskbyultrasoundpesaprotrialstudyprotocolforarandomizedcontrolledtrial
AT torresferran evaluationoftwotreatmentstrategiesforthepreventionofpretermbirthinwomenidentifiedasatriskbyultrasoundpesaprotrialstudyprotocolforarandomizedcontrolledtrial
AT velascoana evaluationoftwotreatmentstrategiesforthepreventionofpretermbirthinwomenidentifiedasatriskbyultrasoundpesaprotrialstudyprotocolforarandomizedcontrolledtrial
AT martinezpayocristina evaluationoftwotreatmentstrategiesforthepreventionofpretermbirthinwomenidentifiedasatriskbyultrasoundpesaprotrialstudyprotocolforarandomizedcontrolledtrial
AT avendanosolacristina evaluationoftwotreatmentstrategiesforthepreventionofpretermbirthinwomenidentifiedasatriskbyultrasoundpesaprotrialstudyprotocolforarandomizedcontrolledtrial
AT evaluationoftwotreatmentstrategiesforthepreventionofpretermbirthinwomenidentifiedasatriskbyultrasoundpesaprotrialstudyprotocolforarandomizedcontrolledtrial